- Home
- ENPH vs AXSM Comparison
ENPH vs AXSM Comparison
Compare ENPH & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENPH
- AXSM
- Stock Information
- Founded
- ENPH 2006
- AXSM 2012
- Country
- ENPH United States
- AXSM United States
- Employees
- ENPH N/A
- AXSM N/A
- Industry
- ENPH Semiconductors
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- ENPH Technology
- AXSM Health Care
- Exchange
- ENPH Nasdaq
- AXSM Nasdaq
- Market Cap
- ENPH 4.2B
- AXSM 5.1B
- IPO Year
- ENPH 2012
- AXSM 2015
- Fundamental
- Price
- ENPH $38.18
- AXSM $118.51
- Analyst Decision
- ENPH Hold
- AXSM Strong Buy
- Analyst Count
- ENPH 33
- AXSM 16
- Target Price
- ENPH $59.90
- AXSM $176.56
- AVG Volume (30 Days)
- ENPH 8.6M
- AXSM 604.8K
- Earning Date
- ENPH 10-21-2025
- AXSM 08-04-2025
- Dividend Yield
- ENPH N/A
- AXSM N/A
- EPS Growth
- ENPH 37.10
- AXSM N/A
- EPS
- ENPH 1.28
- AXSM N/A
- Revenue
- ENPH $1,482,823,000.00
- AXSM $495,033,000.00
- Revenue This Year
- ENPH $12.75
- AXSM $61.62
- Revenue Next Year
- ENPH N/A
- AXSM $59.02
- P/E Ratio
- ENPH $29.93
- AXSM N/A
- Revenue Growth
- ENPH 4.39
- AXSM 69.83
- 52 Week Low
- ENPH $29.89
- AXSM $75.56
- 52 Week High
- ENPH $130.08
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- ENPH 57.91
- AXSM 72.31
- Support Level
- ENPH $34.04
- AXSM $102.67
- Resistance Level
- ENPH $37.39
- AXSM $112.47
- Average True Range (ATR)
- ENPH 2.02
- AXSM 3.25
- MACD
- ENPH 0.79
- AXSM 1.55
- Stochastic Oscillator
- ENPH 96.85
- AXSM 89.74
About ENPH Enphase Energy Inc.
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.